Global Whole Cell Cholera Vaccine Market Size By Type (For Adults, For Children), By Application (Clinical Research Institutes, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Whole Cell Cholera Vaccine Market was valued at USD 285 million in 2023 and is projected to reach USD 470 million by 2031, expanding at a CAGR of 6.5% during the forecast period from 2023 to 2031. The growth is driven by increasing awareness of cholera prevention, growing governmental and non-governmental vaccination initiatives in endemic regions, and rising outbreaks in underdeveloped and densely populated areas. Whole cell cholera vaccines, known for their effectiveness, low cost, and simplified storage, are especially vital for mass immunization programs in Asia and Africa.

Drivers:

Rising Cholera Prevalence in Endemic Regions:

The continued burden of cholera in Africa and South Asia, fueled by inadequate water sanitation and rapid urbanization, is generating significant demand for accessible vaccination strategies, particularly whole cell cholera vaccines.

Global Health Initiatives and Funding:

Organizations such as the WHO, GAVI, and UNICEF are playing a critical role in expanding access to cholera vaccines through funding, distribution programs, and awareness campaigns, particularly targeting children and vulnerable populations.

Cost-Effectiveness and Ease of Administration:

Whole cell cholera vaccines, typically administered orally in two doses, are more affordable and logistically simpler than other alternatives, enhancing their appeal for national immunization programs.

Restraints:

Short-Term Immunity:

Whole cell vaccines often provide shorter duration immunity compared to newer conjugate formulations, leading to the need for booster campaigns, which can strain healthcare resources.

Cold Chain Dependency in Remote Areas:

Despite their simplicity, these vaccines still require temperature-controlled environments. This poses distribution challenges in remote or disaster-affected regions lacking refrigeration infrastructure.

Opportunity:

Strategic Stockpiling and Emergency Response:

As climate change increases the risk of natural disasters and population displacement, the need for rapid-response vaccination is growing. Governmental stockpiling of whole cell cholera vaccines provides an opportunity for manufacturers to supply bulk contracts and emergency kits.

Emerging Market Penetration:

Low-income countries are increasingly integrating cholera vaccines into routine immunization schedules. Manufacturers expanding into these regions through partnerships and local production facilities can capture untapped potential.

Market by System Type Insights:

By system type, the Killed Whole Cell (WC) Vaccines Without B Subunit segment held the largest market share in 2023. These vaccines are widely used due to their cost-effectiveness and reduced adverse reactions. However, the WC Vaccines With Recombinant B Subunit are expected to grow faster during the forecast period, attributed to improved efficacy and broader age group application.

Market by End-use Insights:

Among end-users, Public Health Programs emerged as the dominant segment, accounting for the majority of global demand in 2023. Government-backed vaccination drives, especially in cholera-endemic areas, continue to be the largest revenue source. The Traveler Vaccination segment is also experiencing notable growth due to rising international travel and associated health risks.

Market by Regional Insights:

Asia-Pacific led the global market in 2023 due to frequent cholera outbreaks, large population bases, and strong governmental intervention in countries like India and Bangladesh. Africa follows closely, driven by persistent sanitation challenges and international aid programs. Meanwhile, North America and Europe contribute largely through traveler vaccine demand and R&D investments.

Competitive Scenario:

Key players in the global whole cell cholera vaccine market include Valneva SE, Shantha Biotechnics (Sanofi), Emergent BioSolutions Inc., PaxVax Inc. (now part of Emergent BioSolutions), and EuBiologics Co., Ltd. These companies are focusing on strategic supply agreements, expanding production capabilities, and exploring novel oral formulations to strengthen their market footprint.

Key Market Developments:

2023: EuBiologics expanded its cholera vaccine manufacturing facility to meet rising demand across Southeast Asia and Africa.

2024: Valneva secured a multi-year supply agreement with the WHO for its oral whole cell cholera vaccine.

2025: Emergent BioSolutions announced new data supporting the safety and efficacy of a reformulated oral whole cell cholera vaccine for children under 5 years.

Scope of Work – Global Whole Cell Cholera Vaccine Market

FAQs:

1) What is the current market size of the Global Whole Cell Cholera Vaccine Market?

The market was valued at USD 285 million in 2023.

2) What is the major growth driver of the Global Whole Cell Cholera Vaccine Market?

The major driver is the rising prevalence of cholera in endemic regions and increased global vaccination efforts.

3) Which is the largest region during the forecast period in the Global Whole Cell Cholera Vaccine Market?

Asia-Pacific is expected to remain the largest region due to recurring outbreaks and widespread public health initiatives.

4) Which segment accounted for the largest market share in the Global Whole Cell Cholera Vaccine Market?

The Killed Whole Cell Vaccines Without B Subunit segment held the largest share in 2023.

5) Who are the key market players in the Global Whole Cell Cholera Vaccine Market?

Key players include Valneva SE, Shantha Biotechnics (Sanofi), Emergent BioSolutions Inc., PaxVax Inc., and EuBiologics Co., Ltd.